Invivyd (IVVD) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and platform overview

• Monoclonal antibodies are underutilized in infectious disease, offering potential as both complements and alternatives to vaccines, especially where vaccines are inadequate or impractical.

• The company aims to leverage modern engineering to create potent, long-lasting antibodies, starting with COVID-19 but targeting multiple infectious diseases.

• There is a focus on providing direct, durable protection with minimal burden, positioning antibodies as a natural and intuitive option for disease prevention.

COVID-19 programs and clinical development

• PEMGARDA, an IV-administered antibody, is authorized for COVID-19 prevention in immunocompromised individuals, serving as proof of concept with $50–60 million in revenue and 20%+ growth.

• VYD2311, the next-generation antibody, is in pivotal trials (DECLARATION) for broader use, offering intramuscular administration, expected high protection, and improved safety and tolerability.

• DECLARATION trial is designed to measure reduction in symptomatic COVID-19, with arms for placebo, single dose, and repeat dosing, aiming for 70–90% risk reduction.

• The trial was upsized in April to ensure sufficient power to capture COVID events, with pivotal data expected in late Q3.

• LIBERTY trial will provide head-to-head safety and tolerability data versus mRNA vaccines, with expectations of fewer side effects and improved patient experience.

Market positioning and adoption

• Antibody-based prevention is positioned as a disruptive alternative to vaccines, with potential to become first-line for many, especially those seeking higher protection and fewer side effects.

• Surveys indicate strong patient interest in antibody options, perceived as more natural and intuitive than vaccines.

• Reduced post-administration monitoring time (from two hours to 30 minutes) is expected to facilitate broader adoption and ease of use.